Frankfurt
06.12.24 | 08:01
0,000 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.12.24 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 27.12.2024 | 1.350 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 27.12.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 27.12.2024ISIN NameCA33812R1091 FISSION... ► Artikel lesen | |
| 16.12.24 | Nasdaq Stockholm AB: Delisting of Cyxone AB from Nasdaq First North Growth Market | 243 | GlobeNewswire | On December 9, 2024, Cyxone AB was declared bankrupt by Malmö District Court.
According to item 8.2.7 of the Nasdaq First North Growth Market Rulebook, the exchange may decide to delist the financial... ► Artikel lesen | |
| 06.12.24 | XFRA 4CX: AUSSETZUNG/SUSPENSION | 267 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCYXONE AB SK-,75... ► Artikel lesen | |
| 12.11.24 | Nasdaq Stockholm AB: Cyxone AB receives observation status | 295 | GlobeNewswire | On November 8, 2024, Cyxone AB (the "Company") disclosed a press release with
information on the Company's financial situation.
The rules of Nasdaq First North Growth Market state that an issuer can... ► Artikel lesen | |
| CYXONE Aktie jetzt für 0€ handeln | |||||
| 08.11.24 | Nasdaq Stockholm AB: Lift of Suspension in Cyxone AB at FNSE | 318 | GlobeNewswire | Lifting of Suspension
At Trading Venue FNSE
Issuer: Cyxone AB, LEI: 54930034OH16ROAY4K87
--------------------------------------------------------------------------------
Instruments:... ► Artikel lesen |
5 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 4,730 | -0,76 % | Valneva: Operativer Cashburn deutlich verringert - Umsatz steigt | Valneva hat im ersten Halbjahr 2025 die Gesamterlöse um 37,8 Prozent auf 97,6 Millionen Euro gesteigert. Der Umsatz aus Produktverkäufen stieg um 33,3 Prozent auf 91 Millionen Euro. Das Unternehmen... ► Artikel lesen | |
| NOVAVAX | 8,157 | -0,32 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| COSCIENS BIOPHARMA | 2,460 | -12,77 % | COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company's listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,240 | +2,28 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update | Clinical trial advances for INSTASYL siRNA lead product candidate PH-7625th cohort enrolling patients in on-going clinical studyKing of Prussia, Pennsylvania--(Newsfile Corp. - August 14, 2025) - Phio... ► Artikel lesen | |
| ORAGENICS | 1,140 | -3,80 % | Oragenics Q2 2025 Shareholder Update | Advancing Brain-First Recovery Platform Toward Clinical MilestonesPioneering Intranasal Therapeutics for Concussion SARASOTA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American:... ► Artikel lesen | |
| LEXICON PHARMACEUTICALS | 1,031 | -2,37 % | Lexicon Pharmaceuticals, Inc.: Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates | Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,990 | +23,75 % | CSTONE PHARMA-B (02616): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2025 | ||
| OUTLOOK THERAPEUTICS | 2,032 | +1,40 % | Outlook Therapeutics, Inc.: Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update | First commercial sales of LYTENAVA (bevacizumab gamma) achieved in EuropeONS-5010/LYTENAVA (bevacizumab-vikg) Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, in the United States... ► Artikel lesen | |
| GENSCRIPT BIOTECH | 1,899 | +1,25 % | GENSCRIPT BIO (01548): VOLUNTARY ANNOUNCEMENT: FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025 OF A LISTED ASSOCIATE - LEGEND BIOTECH CORPORATION | ||
| KRYSTAL BIOTECH | 127,95 | -0,43 % | Krystal Biotech, Inc.: Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté | KB304 designed to deliver collagen and elastin to restore skin naturally Conference call to discuss results scheduled for Thursday, July 24, 2025 at 4:30pm ET PITTSBURGH, July 24, 2025 (GLOBE... ► Artikel lesen | |
| ALIGOS THERAPEUTICS | 6,550 | 0,00 % | Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos", "Company"), a clinical stage biopharmaceutical company focused on improving patient... ► Artikel lesen | |
| Q32 BIO | 1,620 | -2,41 % | Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update | -- Dosing of patients in Part A open-label extension (OLE) and Part B of SIGNAL-AA ongoing; SIGNAL-AA Part B topline data readout on-track for 1H'26 --
-- Strengthened... ► Artikel lesen | |
| LEAP THERAPEUTICS | 0,212 | -7,02 % | Leap Therapeutics, Inc.: Leap Therapeutics Reports Second Quarter 2025 Financial Results | CAMBRIDGE, Mass., Aug. 14, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology... ► Artikel lesen | |
| ACTINOGEN | 0,014 | -3,45 % | Actinogen Medical - XanaMIA study enrols 100th patient | Actinogen Medical announced on 30 June that it has recruited the 100th patient for its ongoing XanaMIA Phase IIb/III study assessing lead candidate Xanamem (emestedastat) in patients with biomarker-positive... ► Artikel lesen | |
| XENETIC BIOSCIENCES | 2,770 | 0,00 % | Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results | Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and further develop its program combining systemic DNase I with CAR T-cell therapiesEnded the quarter... ► Artikel lesen |
CYXONE AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,000 Euro und damit 0,00 % im Plus.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYXONE AB finden Sie auf Wallstreet Online.